Introduction {#s0005}
============

Gastric cancer is the leading cause of cancer death worldwide, with an incidence of 18.9 of 100,000 per year [@bb0005]. The incidence of gastric cancer is estimated to be 934,000 cases, with 56% of new cases occurring in East Asia [@bb0010]. According to the Central Tumor Registry data for 2002, gastric cancer accounts for 20.8% of all cancers in Korea [@bb0015]. Although the overall survival (OS) of gastric cancer has been improved owing to the application of a national fiber optic esophagogastroduodenoscopy screening program in adults older than 40 years in Korea, a large proportion of patients are still diagnosed at the metastatic stage. The median survival time following cytotoxic chemotherapy is still less than 1 year; and thus metastatic gastric cancer remains a therapeutic challenge for medical oncologists [@bb0005]. The role of molecularly targeted therapy has not been adequately explored in gastric cancer compared with other common solid tumors such as breast, colorectal, or non--small cell lung cancer.

Insulin-like growth factors (*IGF-I* and *-II*) and their receptors play a pivotal role in regulating cell proliferation, differentiation, and apoptosis [@bb0020]. Aberrant expression and regulation of these proteins have been implicated in the development and prognosis of many human cancers [@bb0025; @bb0030]. There are at least six *IGF*-binding proteins (*IGFBPs*). *IGFBP-3* is the most abundant *IGFBP* found in serum and binds the majority of serum *IGFs* [@bb0035]. *IGFBP-3* regulates *IGF* bioactivity by sequestering *IGF* in the extracellular milieu, thereby inhibiting its mitogenic and antiapoptotic actions. In addition to its *IGF*-dependent function, *IGFBP-3* also has *IGF*-independent antiproliferative and proapoptotic effects that seem to involve cell surface receptors for *IGFBP-3* [@bb0020; @bb0040; @bb0045; @bb0050; @bb0055]. *IGFBP-3* is expressed in most human tissue and in a variety of cell lines, including those of gastric origin [@bb0060; @bb0065]. Studies of gastric cancer cell lines have shown that *IGFBP-3* can markedly inhibit the response of gastric cancer cells to *IGF* [@bb0060]. A recent study also reported that *IGFBP-3* is protective against the development of gastric carcinoma by preventing the formation of intestinal metaplasia, and improves the prognosis of gastric cancer [@bb0030].

The integral role of epigenetic mechanisms such as promoter hypermethylation of tumor suppressor genes has become ever more apparent over the past decade [@bb0070]. Promoter hypermethylation is widespread in some cancers, occurs in the early stages of cancer development, and has been correlated with clinicopathologic features indicative of a poor prognosis, thus indicating the potential of gene hypermethylation as a marker of clinically significant disease [@bb0075]. Promoter hypermethylation has been proposed as a mechanism for the transcriptional silencing of *IGFBP-3* in hepatocellular carcinomas [@bb0080], early-stage non--small cell lung cancer [@bb0085], prostate cancer [@bb0090; @bb0095], and in cancers of the bladder and ovary [@bb0100; @bb0105].

We undertook this study to assess the impact of *IGFBP-3* methylation on survival of early-stage gastric cancer patients. Statistical analysis was performed to investigate the correlations between methylation and clinical and pathologic parameters.

Methods {#s0010}
=======

Patients and Tissues {#s0015}
--------------------

We previously reported the outcomes of 544 stage II to IV (M0) gastric cancer patients who received adjuvant chemoradiation therapy after curative surgery [@bb0110]. All patients were Korean and were staged by American Joint Committee on Cancer sixth edition. The postoperative adjuvant treatment adopted was the same as that used for the INT-0116 (SWOG-9008) trial, the results of which were previously reported [@bb0115]. Between these patients and an additional 23 stage IB patients who were included in our previous study, formalin-fixed, paraffin-embedded primary tumor tissues were available from 482 patients. All patients provided written informed consent according to institutional guidelines, and the study was approved by the Institutional Review Board. Among 482 patients, 138 stage IB/II gastric cancer patients were analyzed in this study.

Gastric Cancer Cell Lines {#s0020}
-------------------------

Human gastric carcinoma cells AGS, KATO-III, MKN-1, MKN-28, MKN-45, MKN-74, N87, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, and SNU-719 were purchased from the Korean Cell Line Bank (Seoul, Korea). YCC-1, YCC2, YCC-3, and YCC-7 were kindly provided by Dr. Hyun Cheol Chung (Yonsei Cancer Center, Seoul, Korea). OCUM-2M was kindly provided by Dr. Masakazu Yashiro (Osaka City University, Osaka, Japan). YCC-1, YCC-2, YCC-3, and YCC-7 were maintained in Dulbecco's modified Eagle's medium (Gibco-BRL, Carlsbad, CA) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM glutamine. All other cell lines were cultured in RPMI-1640 medium (Gibco-BRL) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 2 mM glutamine. All cells were incubated in a humidified atmosphere contained 5% CO~2~ at 37°C.

Bisulfite Modification {#s0025}
----------------------

Bisulfite treatment of DNA was performed using the EpiTect Bisulfite Kit (QIAGEN) according to manufacturer's instructions. Briefly, 1 μg of genomic DNA in 20 μl of water was combined with 85 μl of bisulfate mix and 35 μl of DNA protection buffer. Bisulfate conversion of DNA was performed using the following conditions: denaturation at 99°C for 5 minutes, incubation at 60°C for 25 minutes, denaturation at 99°C for 5 minutes, incubation at 60°C for 85 minutes, denaturation at 99°C for 5 minutes, incubation at 60°C for 175 minutes, and hold at 20°C. The bisulfite-converted DNA was mixed with 560 μl of Buffer BL, applied to a spin column, and centrifuged at 12,000 rpm for 1 minute. The flow-through was discarded and the column was washed with 500 μl of Buffer BW. Buffer BD (500 μl) was applied to the column, which was incubated at room temperature for 15 minutes. The column was centrifuged to remove Buffer BD and then washed twice with Buffer BW (500 μl). Residual Buffer BW was removed by an additional spin (12,000 rpm for 1 minute). Buffer EB (20 μl) was added to the column to elute the DNA. The DNA concentration was determined using a Nano-drop spectrophotometer.

Methylation-Specific Polymerase Chain Reaction (MS-PCR) for Quantitative DNA Methylation Analysis {#s0030}
-------------------------------------------------------------------------------------------------

The primers and probe for *IGFBP-3* were as follows: *IGFBP3*-F, 5ʹ-GTT TCG GGC GTG AGT ACG A-3ʹ; *IGFBP3*-R, 5ʹ-GAA TCG ACG CAA ACA CGA CTA C-3ʹ; and I*GFBP3*-probe, 6FAM-5ʹ-TCG GTT GTT TAG GGC GAA GTA CGG G-3ʹ-TAMRA. The collagen 2A1 gene (COL2A1) was used to normalize for the amount of input bisulfite-converted DNA. The primers and probe for COL2A1 were as follows: COL2A1-F, 5ʹ-TCT AAC AAT TAT AAA CTC CAA CCA CCA A-3ʹ; COL2A1-R, 5ʹ-GGG AAG ATG GGA TAG AAG GGA ATA T-3ʹ; and COL2A1-probe, VIC-5ʹ-CCT TCA TTC TAA CCC AAT ACC TAT CCC ACC TCT AAA-TAMRA-3ʹ. Reactions were done in triplicate with genomic DNA at 5 ng, primers at 900 nmol/l, probes at 250 nmol/l, and TaqMan Universal PCR reagent under standard thermocycling conditions. After initial denaturating for 10 minutes at 95°C, 45 cycles at 95°C for 15 seconds, 60°C for 1 minute, and 72°C for 1 minute were carried out, followed by a final extension for 5 minutes at 72°C. AsPC-1 cell line was included as negative control sample to compare methylation results. The percentage of methylated reference at a specific locus was calculated by dividing the ratio of GENE/COL2A1 template in a sample by the ratio of GENE/COL2A1 template in *Sss*I-treated human genomic DNA (presumably fully methylated) and multiplying this value by 100.

DNA Extraction {#s0035}
--------------

One hundred thirty-eight stage IB/II gastric cancer patients were evaluated for the methylation status of the *IGFBP-3* promoter. Fifty-four of those patients had nonneoplastic and noninfiltrated gastric mucosa also evaluated. DNA was extracted from five 10-μm formalin-fixed, paraffin-embedded sections containing a representative portion of each tumor block using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). A pathologist reviewed each slide and verified the presence of adequate tumor tissue with greater than 50% representative malignant cells.

Statistical Analyses {#s0040}
--------------------

*Disease-free survival* (DFS) was defined as the time from surgery to the first relapse of cancer or death of any cause. Overall survival was calculated from the date of surgery to the date of death. OS and DFS were calculated using the Kaplan-Meier method. Correlation analyses were performed using the two-sided *χ*^2^ test or Fisher exact test. Differences in DFS and OS were compared using log-rank tests and Cox proportional hazard analysis. A *P* value of less than .05 was considered statistically significant.

Results {#s0045}
=======

The Status of IGFBP-3 Methylation in Gastric Cancer Cell Lines {#s0050}
--------------------------------------------------------------

*IGFBP-3* methylation pattern was measured by MS-PCR in 22 known gastric cell lines (KATO-III, OCUM-2M, AGS, N87, MKN-1, MKN-28, MKN-45, MKN-74, YCC-1, YCC-2, YCC-3, YCC-7, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, and SNU-719). The clinical information of these gastric cell lines was summarized in [Table 1](#t0005){ref-type="table"}. In methylation analysis by MSP of *IGFBP3*, all gastric cell lines with methylated band revealed IGFBP3 methylation of more than 80% in quantitative PCR. The representative results are shown in [Figure 1](#f0005){ref-type="fig"}.

Correlation Between IGFBP-3 Methylation and Clinical Variables {#s0055}
--------------------------------------------------------------

The general clinical characteristics of 138 patients analyzed for the status of IGFBP-3 methylation are presented in [Table 2](#t0010){ref-type="table"}. The *IGFBP-3* promoter was methylated in 26 of 138 stage IB/II gastric cancer samples. In univariate analysis, there was no statistically significant association between the hypermethylation of *IGFBP-3* and clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade. The age of 138 patients with stage IB/II gastric cancer ranged from 23 to 70 years (median, 54.5 years). Eighty-one (58.7%) of the patients were diffuse type according to Lauren classification, and the majority (70.3%) of patients were male.

Impact of IGFBP-3 Methylation on Recurrence and Survival {#s0060}
--------------------------------------------------------

We performed survival analyses according to the methylation status of the *IGFBP-3* promoter ([Figure 2](#f0010){ref-type="fig"}). Disease recurrence was observed in 34 (24.6%) of 138 patients during the median follow-up period of 110.7 months. Stage IB/II gastric cancer patients with a hypermethylated *IGFBP-3* promoter had a similar DFS following curative surgery as compared with those without *IGFBP-3* methylation (5-year DFS: 73.1% vs 79.5%; *IGFBP-3* methylation (+) vs *IGFBP-3* methylation (−); *P* = .7840). Moreover, gastric cancer patients with *IGFBP-3* methylation also demonstrated similar OS following curative surgery as compared with those without *IGFBP-3* methylation (5-year OS: 80.7% vs 80.3%; *IGFBP-3* methylation (+) vs *IGFBP-3* methylation (−); *P* = .7848). The following variables were tested using backward stepwise Cox proportional hazards regression modeling: age (≤ 60 vs \> 60), Lauren classification, sex (male vs female), tumor infiltration (T1/T2 vs T3/T4), lymph node (N0/N1 vs N2/N3), histologic grade, and the methylation status of the *IGFBP-3* promoter. For DFS and OS in all patients, none of the factors tested had a predictive role with statistical significance at the univariate and multivariate level.

In subgroup analyses, women, but not men, showed a trend toward poorer prognosis for DFS and OS in the subset of patients with *IGFBP-3* methylation as compared with those without *IGFBP-3* methylation (8-year DFS: 55.6% vs 71.6%, *P* = .3694 and 8-year OS: 55.6% vs 68.4%, *P* = .491, respectively; [Figure 3](#f0015){ref-type="fig"}) even with no statistical significance.

Discussion {#s0065}
==========

It has been known that the *IGF-IGFBP* system might play an important role in the initiation, progression, and metastasis of gastric cancer [@bb0030; @bb0060]. *IGFBP-3*, one of six members of the *IGFBP* family, regulates *IGF* bioactivity by sequestering *IGFs* away from the *IGF* receptor in the extracellular milieu, thereby inhibiting the mitogenic and antiapoptotic action of *IGFs* [@bb0020; @bb0050]. A negative correlation between serum *IGFBP-3* levels and human cancer risk suggests a protective role of *IGFBP-3* against the effects of systemic IGFs [@bb0120; @bb0125]. Zhang et al. [@bb0030] reported a significantly higher percentage of positive *IGFBP-3* staining in the tumor tissues of patients with well or moderately differentiated tumors than those with poorly differentiated tumors, indicating that *IGFBP-3* may be associated with a better prognosis.

DNA methylation, which is the major form of epigenetic information in mammalian cells, has profound effects on the mammalian genome, including transcriptional repression, chromatin structure modulation, X-chromosome inactivation, genomic imprinting, and suppression of the detrimental effects of repetitive and parasitic DNA sequence on genomic integrity [@bb0130; @bb0135; @bb0140]. A recent study using a monoclonal antibody specific for 5-methylcytosine to evaluate for the status of global DNA methylation suggests that alteration in DNA methylation is an important epigenetic difference in susceptibility to the development of human cancer [@bb0145]. Genomic methylation patterns are frequently altered in tumor cells, with global hypomethylation accompanying region-specific hypermethylation events. CpG islands in specific regions of the promoter have been described as a common epigenetic mechanism for the silencing of tumor suppressor genes in cancer and as a regulator of growth in cancers [@bb0140]. Promoter hypermethylation has been proposed as a mechanism for transcriptional silencing of *IGFBP-3* in hepatocellular carcinoma [@bb0080], early-stage non--small cell lung cancer [@bb0085], prostate cancer [@bb0090; @bb0095], and cancers of the bladder and ovary [@bb0100; @bb0105]. Moreover, it was shown that this hypermethylation of *IGFBP-3* occurs as an early event in cancer carcinogenesis. However, the role of *IGFBP-3* methylation in early-stage gastric cancer had not been evaluated until now.

The present study is the first to assess the impact of *IGFBP-3* methylation on survival in early-stage gastric cancer patients. We found that clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the *IGFBP-3* promoter. In addition, no significant difference in survival outcomes of stage IB/II gastric cancer patients according to the status of *IGFBP-3* methylation was observed. However, this finding should be interpreted with caution. In our study, most patients (87%), with the exception of 18 patients with stage IB cancers, received adjuvant chemoradiation therapy after curative surgery. Treatments such as adjuvant chemoradiation may change the impact of *IGFBP-3* methylation on survival of early-stage gastric cancer patients. In this study, the 5-year survival rate for patients with IB/II gastric cancer was about 80%. Therefore, the impact of *IGFBP-3* methylation on survival may have been diluted by good survival outcomes in the analyzed patients.

The most interesting finding of this study was that women, but not men, showed a trend toward poorer prognosis for DFS and OS in the subset of patients with *IGFBP-3* methylation as compared with those without *IGFBP-3* methylation. This observation may be caused by a difference in *IGFBP-3* values according to sex. Lin et al. reported that women had significantly higher *IGFBP-3* values than men and that women older than 50 years showed a significant reduction in *IGF-I/IGFBP-3* molar ratio. Thus, *IGFBP-3* methylation may have a more powerful influence on survival outcomes in female than male patients [@bb0150].

Previous studies have shown that the transcriptional activity of the methylated *IGFBP-3* promoter is restored by treatment with the demethylating agent 5'-aza-dC in some human cancers, including hepatocellular carcinoma and non--small cell lung cancer [@bb0080; @bb0085]. However, 5'-aza-dC treatment restores *IGFBP-3* expression in only a portion of those cancer cell lines in which the promoter is methylated [@bb0085]. These findings suggest that the mechanisms regulating *IGFBP-3* expression in human cancer cells are diverse and complex. Thus, the multifaceted nature of the processes involved in the regulation of *IGFBP-3* expression might affect the results of our study. Future research will investigate other mechanisms related to *IGFBP-3* expression and silencing in gastric cancer.

The mechanisms of *IGFBP-3* expression and silencing in gastric cancer have not been fully elucidated. However the status of *IGFBP-3* methylation as measured by MS-PCR may be good predictive factor for survival in specific subgroups of patients with early-stage gastric cancer undergoing curative surgery. Further research is needed to better understand the role of *IGFBP-3* in gastric cancer.
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###### 

The Information of 23 Gastric Cell Lines Analyzed for *IGFBP-3* Methylation

  Status                  Gender   Histologic Subtype   Origin
  ----------------------- -------- -------------------- ------------------------------
  Methylated IGFBP-3                                    
   KATO-III               Male     Poorly               Pleural effusion, metastatic
   OCUM-2 M               Female   Poorly               Stomach, primary
   AGS                    Female   Poorly               Stomach, primary
   N87                    Male     Well                 Liver, metastatic
   MKN-28                 Female   Moderate             Lymph node, metastatic
   MKN-45                 Female   Poorly               Liver, metastatic
   MKN-74                 Male     Moderate             Liver, metastasis
   SNU-16                 Female   Poorly               Ascites, metastatic
   SNU-216                Female   Moderate             Lymph node, metastatic
   SNU-484                Male     Poorly               Stomach, primary
   SNU-601                Male     Poorly               Ascites, metastatic
   SNU-620                Female   Poorly               Ascites, metastatic
   SNU-638                Male     Poorly               Ascites, metastatic
   SNU-719                Male     Moderate             Stomach, primary
  Un-Methylated IGFBP-3                                 
   MKN-1                  Male     Adenosquamous        Lymph node, metastatic
   YCC-1                  Male     NA                   Ascites, metastatic
   YCC-2                  Male     NA                   Ascites, metastatic
   YCC-3                  Male     NA                   Ascites, metastatic
   YCC-7                  Male     NA                   Ascites, metastatic
   SNU-1                  Male     Poorly               Stomach, primary
   SNU-5                  Female   Poorly               Ascites, metastatic
   SNU-668                Male     Poorly               Ascites, metastatic

###### 

Clinical Features and *IGFBP-3* Methylation in Stage IB/II

                                               No. of Cases (N = 138) (%)   *IGFBP-3* Methylation         
  -------------------------------------------- ---------------------------- ----------------------- ----- -------
  **Age**                                                                                                 
   ≤ 60                                        100(72.5)                    21                      79    .293
   \> 60                                       38 (27.5)                    5                       33    
  **Lauren classification**                                                                               
   Intestinal                                  56 (40.6)                    8                       48    .109
   Diffuse                                     81 (58.7)                    17                      64    
   Intermediate                                1 (0.7)                      1                       0     
  **Sex**                                                                                                 
   Male                                        97 (70.3)                    17                      80    .543
   Female                                      41 (29.7)                    9                       32    
  **Tumor infiltration**                                                                                  
   T1/T2                                       118 (85.5)                   23                      95    .766
   T3/T4                                       20 (14.5)                    3                       17    
  **Lymph node metastasis**                                                                               
   N0/N1                                       135 (97.8)                   26                      109   1.000
   N2/N3                                       3 (2.2)                      0                       3     
  **Histologic grade (adenocarcinoma only)**                                                              
   Well/moderately differentiated              52 (37.7)                    8                       44    .419
   Poorly differentiated/Other types           86 (62.3)                    18                      68    
